CSI Market
Sign In | Register

Dyne Therapeutics Inc (DYN) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access DYN quarterly Cash Flow →
The table below presents a historical view of Dyne Therapeutics Inc's cash flow activity, supporting analysis of liquidity trends over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-446.21
Depreciation & amortization2.05
Amortization of Other Assets0.00
Minority interests0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
Sale of assets0.00
Gain (Loss) on Disposition of Assets, Total0.10
Share-based Compensation45.85
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Deconsolidation Gain Or Loss Amount-
Tangible Asset Impairment Charges0.16
Income Loss From Equity Method Investments Net Of Dividends Or Distribution Cash Flow Impact-
Gain Loss From Price Risk Management Activity-
Gain Loss From Price Risk Management Activity Affiliates-
Impairment Provisions And Other Charges-
Impairment Loss For Related Party Receivable-
Unrealized Gain Loss On Derivatives Related Parties-
Gains Losses On Sales Of Assets-
Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss Included In Other Income-
Increase Decrease From Affiliate Transactions-
Income taxes0.00
Unrealized Gain (Loss) on Derivatives0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Other Operating Liabilities8.25
Accrued liabilities0.00
Risk-management0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.99
Other Working Capital-12.64
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.75
Discontinued operations0.00
Net Cash flow from Operating Activities-403.21
Investing Activities
Capital Expenditures-20.71
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities17.85
Payments to Acquire Marketable Securities-180.53
Proceeds from other investments0.00
Proceeds From Affiliate Transactions154.64
Increase (Decrease) in Restricted Cash0.00
Noncontrolling interest0.00
Proceeds from Investments0.00
Purchases of Investments0.00
Purchases of non-current assets0.00
Acquisition Net of Cash Acquired0.00
Proceeds from Equity Method Investment, Dividends or Distributions, Return of Capital0.00
Sale of businesses0.00
Proceeds from sale of assets0.00
Notes receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-28.75
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.56
Long-term debt - borrowings148.26
Long-term debt - repayments0.00
Noncontrolling interest0.00
Issuances / -repurchases of Comm. Stock148.65
Exercise of stock options0.00
Issuances / -repurchases of Pref. Stock0.00
Discontinued Operations0.00
Other financing activities net0.00
Other net-437.46
Payments Relatedto Bankruptcy Financing-
Dividends paid to minority interests0.00
Dividends paid0.00
Net Cash Flow from Financing Activities890.31
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-423.92
Total Cash Flow458.35
4 historic quarters locked

Sign in to unlock the full Dyne Therapeutics Inc cash flow history.

Sign In Create Free Account

About Dyne Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: March 2, 2026
  • Source: dyn-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-084178

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document